Navigation Links
Telik Reports Preclinical Results at AACR Annual Meeting
Date:4/28/2009

PALO ALTO, Calif., April 28 /PRNewswire-FirstCall/ -- Telik, Inc. (Nasdaq: TELK) announced results of studies on two of its drug development programs that were presented at the 100th annual meeting of the American Association for Cancer Research (AACR) in Denver, CO. The abstracts can be found on the Telik website, www.telik.com.

In vivo Characterization and Mechanism of Action of Orally Active Aurora Kinase/ VEGFR Inhibitors; Abstract # 1764

Aurora kinases are Ser/Thr kinases that play an important role in chromosome alignment, segregation and cytokinesis during mitosis. Over-expression of Aurora kinases has been demonstrated in both solid tumors and leukemia and is considered to be associated with aneuploidy and carcinogenesis. Inhibition of Aurora kinase activity induces growth arrest and apoptosis in cells and leads to tumor-growth inhibition in xenograft models of human cancer.

Key findings:

  • Telik researchers presented additional data for a novel class of small molecule drug candidates showing strong and equipotent inhibition of Aurora kinase and VEGFR kinase, with IC50s less than 10 nM.
  • These compounds induced growth arrest, polyploidy and apoptosis in human cancer cell lines, such as HCT116 (colon), HL60 (promyelocytic leukemia) and A549 (lung) - reflecting cell lines with intact or defective p53-dependent post-mitotic checkpoints.
  • More than 80% inhibition of tumor growth was seen in an HL60 xenograft model following a once daily oral dosing schedule.
  • Drug inhibition of aurora kinase and VEGFR activity in tumor samples of treated animals was established by analysis of markers, such as histone H3 phosphorylation and CD31.

Anti-Tumor Efficacy and Molecular Mechanism of TLK58747; Abstract # 4515

Telik researchers identified a novel alkylating agent, TLK58747, which functions as a prodrug, without the need for enzymatic processing, and which does not release an activation byproduct known to be associated with toxicity of other alkylating agents (acrolein).

Key findings:

  • TLK58747 inhibited the growth of nine established cell lines of various tumor types and retained its effectiveness against cancer cell lines resistant to standard cancer chemotherapeutics including adriamycin, paclitaxel, and carboplatin.
  • Treatment of human cancer cells with TLK58747 led to the activation of the DNA damage-response pathway, and produced G2/M cell cycle arrest in human solid tumor cell lines. The resulting apoptosis or senescence of these cells may depend on their p53 status.
  • In vivo, TLK58747 demonstrated significant antitumor activity both orally and parenterally against a wide variety of human tumor types, including breast, pancreatic, prostate, and colorectal carcinomas, as well as glioma and promyelocytic leukemia.

Telik, Inc. of Palo Alto, CA, is a clinical stage drug development company focused on discovering and developing small molecule drugs to treat cancer and inflammatory diseases. The company's most advanced investigational drug candidates in clinical development are TELINTRA(R), a modified glutathione analog for the treatment of cytopenias due to myelodysplastic syndrome or chemotherapy, and TELCYTA(R), a tumor-activated prodrug for the treatment of advanced ovarian cancer and non-small cell lung cancer. Telik's product candidates were discovered using its proprietary drug discovery technology, TRAP(R), which enables the rapid and efficient discovery of small molecule drug candidates.

TELIK, the Telik logo, TELINTRA, TELCYTA and TRAP are trademarks or registered trademarks of Telik, Inc.


'/>"/>
SOURCE Telik, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Telik Announces Presentation and Webcast at Bear Stearns Healthcare Conference
2. Telik Announces Presentation and Webcast at UBS Global Life Sciences Conference
3. Telik Announces Presentation and Webcast at JPMorgan Healthcare Conference
4. Telik Announces Year-End Financial Release, Conference Call and Webcast
5. Telik Announces Revised Date for Year-End Financial Release, Conference Call and Webcast
6. Telik Announces Fourth Quarter and 2007 Year End Financial Results and 2008 Guidance
7. Telik Presents Preclinical Data at 99th Annual Meeting of the American Association for Cancer Research
8. Telik Announces First Quarter 2008 Financial Results
9. Telik Announces Presentation and Webcast at Needham Biotechnology Conference
10. Telik Announces Publication of Diabetes Research in Bioorganic & Medicinal Chemistry Letters
11. Telik Announces 2008 Second Quarter Financial Release, Conference Call and Webcast
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... 2016   EpiBiome , a precision microbiome engineering ... debt financing from Silicon Valley Bank (SVB). The financing ... advance its drug development efforts, as well as purchase ... "SVB has been an incredible strategic partner to us ... bank would provide," said Dr. Aeron Tynes Hammack ...
(Date:6/23/2016)... Ky. , June 23, 2016 ... two Phase 1 clinical trials of its complement ... placebo-controlled, single and multiple ascending dose studies designed ... pharmacodynamics (PD) of subcutaneous injection in healthy adult ... subcutaneously (SC) either as a single dose (ranging ...
(Date:6/23/2016)... San Francisco, CA (PRWEB) , ... June 23, ... ... capture (EDC) software, is exhibiting at the Pennsylvania Convention Center and will showcase ... DIA Annual conference. ClinCapture will also be presenting a scientific poster on Disrupting ...
(Date:6/23/2016)... June 23, 2016 ReportsnReports.com ... report to its pharmaceuticals section with historic and ... and much more. Complete report on ... pages, profiling 15 companies and supported with 261 ... http://www.reportsnreports.com/reports/601420-global-cell-culture-media-industry-2016-market-research-report.html . The Global Cell ...
Breaking Biology Technology:
(Date:6/15/2016)... , June 15, 2016 ... market report titled "Gesture Recognition Market by Application Market - Global ... 2016 - 2024". According to the report, the  global ... billion in 2015 and is estimated to grow ... 48.56 billion by 2024.  Increasing application ...
(Date:6/2/2016)... The Department of Transport Management (DOTM) ... million US Dollar project, for the , Supply ... Enrolment, and IT Infrastructure , to ... implementation of Identity Management Solutions. Numerous renowned international vendors participated ... was selected for the most compliant and innovative ...
(Date:5/20/2016)... -- VoiceIt is excited to announce its new marketing ... working together, VoiceIt and VoicePass will offer an ... slightly different approaches to voice biometrics, collaboration between ... Both companies ... "This marketing and technology partnership allows VoiceIt ...
Breaking Biology News(10 mins):